StreetInsider.com News Articles

ME Therapeutics Scientific and Corporate Update

Fri, 30 Jan 2026 09:00:00 -0500

VANCOUVER, British Columbia--(BUSINESS WIRE)-- ME Therapeutics Holdings Inc. (“ME Therapeutics” or the “Company”) (CSE: METX) (FSE: Q9T), a publicly listed biotechnology company working on novel cancer fighting drugs that reprogram and redirect immune cells to fight cancer, is pleased to provide a corporate update and an outline of its strategic positioning within the rapidly emerging in vivo immune cell engineering and chimeric antigen receptor (CAR) space.

ME Therapeutics continues to focus its attention to scientifically validated cancer targets to develop a diverse pipeline of drug candidates to move into clinical testing. Our pipeline candidates include therapeutic mRNAs designed

ME Therapeutics Scientific and Corporate Update

Fri, 30 Jan 2026 09:00:00 -0500

ME Therapeutics Scientific and Corporate Update

Fri, 30 Jan 2026 09:00:00 -0500

ME Therapeutics Scientific and Corporate Update

Fri, 30 Jan 2026 09:00:00 -0500

ME Therapeutics Scientific and Corporate Update

Fri, 30 Jan 2026 09:00:00 -0500

ME Therapeutics Scientific and Corporate Update

Fri, 30 Jan 2026 09:00:00 -0500

ME Therapeutics Scientific and Corporate Update

Fri, 30 Jan 2026 09:00:00 -0500

ME Therapeutics Scientific and Corporate Update

Fri, 30 Jan 2026 09:00:00 -0500

ME Therapeutics Attending JP Morgan Healthcare Conference

Tue, 06 Jan 2026 16:00:00 -0500

VANCOUVER, British Columbia--(BUSINESS WIRE)-- ME Therapeutics Holdings Inc. (“ME Therapeutics” or the “Company”) (CSE: METX) (FSE: Q9T), a publicly listed biotechnology company discovering and developing novel drugs to reprogram the immune response to cancer, is pleased to share that company representatives will attend and participate in one-on-one meetings at the 44th annual JP Morgan Healthcare Conference from January 12 to 15, 2026 in San Francisco, California.

At the conference, CEO and Co-Founder Dr. Salim Dhanji will meet with investors to highlight how ME Therapeutics is reprogramming myeloid cells in the tumour microenvironment to directly target cancer cells as

ME Therapeutics Attending JP Morgan Healthcare Conference

Tue, 06 Jan 2026 16:00:00 -0500

VANCOUVER, British Columbia--(BUSINESS WIRE)-- ME Therapeutics Holdings Inc. (“ME Therapeutics” or the “Company”) (CSE: METX) (FSE: Q9T), a publicly listed biotechnology company discovering and developing novel drugs to reprogram the immune response to cancer, is pleased to share that company representatives will attend and participate in one-on-one meetings at the 44th annual JP Morgan Healthcare Conference from January 12 to 15, 2026 in San Francisco, California.

ME Therapeutics Attending JP Morgan Healthcare Conference

Tue, 06 Jan 2026 16:00:00 -0500

VANCOUVER, British Columbia--(BUSINESS WIRE)-- ME Therapeutics Holdings Inc. (“ME Therapeutics” or the “Company”) (CSE: METX) (FSE: Q9T), a publicly listed biotechnology company discovering and developing novel drugs to reprogram the immune response to cancer, is pleased to share that company representatives will attend and participate in one-on-one meetings at the 44th annual JP Morgan Healthcare Conference from January 12 to 15, 2026 in San Francisco, California.

ME Therapeutics Attending JP Morgan Healthcare Conference

Tue, 06 Jan 2026 16:00:00 -0500

VANCOUVER, British Columbia--(BUSINESS WIRE)-- ME Therapeutics Holdings Inc. (“ME Therapeutics” or the “Company”) (CSE: METX) (FSE: Q9T), a publicly listed biotechnology company discovering and developing novel drugs to reprogram the immune response to cancer, is pleased to share that company representatives will attend and participate in one-on-one meetings at the 44th annual JP Morgan Healthcare Conference from January 12 to 15, 2026 in San Francisco, California.

ME Therapeutics Attending JP Morgan Healthcare Conference

Tue, 06 Jan 2026 16:00:00 -0500

VANCOUVER, British Columbia--(BUSINESS WIRE)-- ME Therapeutics Holdings Inc. (“ME Therapeutics” or the “Company”) (CSE: METX) (FSE: Q9T), a publicly listed biotechnology company discovering and developing novel drugs to reprogram the immune response to cancer, is pleased to share that company representatives will attend and participate in one-on-one meetings at the 44th annual JP Morgan Healthcare Conference from January 12 to 15, 2026 in San Francisco, California.

ME Therapeutics Attending JP Morgan Healthcare Conference

Tue, 06 Jan 2026 16:00:00 -0500

VANCOUVER, British Columbia--(BUSINESS WIRE)-- ME Therapeutics Holdings Inc. (“ME Therapeutics” or the “Company”) (CSE: METX) (FSE: Q9T), a publicly listed biotechnology company discovering and developing novel drugs to reprogram the immune response to cancer, is pleased to share that company representatives will attend and participate in one-on-one meetings at the 44th annual JP Morgan Healthcare Conference from January 12 to 15, 2026 in San Francisco, California.

ME Therapeutics Attending JP Morgan Healthcare Conference

Tue, 06 Jan 2026 16:00:00 -0500

VANCOUVER, British Columbia--(BUSINESS WIRE)-- ME Therapeutics Holdings Inc. (“ME Therapeutics” or the “Company”) (CSE: METX) (FSE: Q9T), a publicly listed biotechnology company discovering and developing novel drugs to reprogram the immune response to cancer, is pleased to share that company representatives will attend and participate in one-on-one meetings at the 44th annual JP Morgan Healthcare Conference from January 12 to 15, 2026 in San Francisco, California.

ME Therapeutics Attending JP Morgan Healthcare Conference

Tue, 06 Jan 2026 16:00:00 -0500

VANCOUVER, British Columbia--(BUSINESS WIRE)-- ME Therapeutics Holdings Inc. (“ME Therapeutics” or the “Company”) (CSE: METX) (FSE: Q9T), a publicly listed biotechnology company discovering and developing novel drugs to reprogram the immune response to cancer, is pleased to share that company representatives will attend and participate in one-on-one meetings at the 44th annual JP Morgan Healthcare Conference from January 12 to 15, 2026 in San Francisco, California.

ME Therapeutics Granted Licence for CD22 Nanobody Asset to Expand Next-Gen In Vivo CAR Cell Therapy Program

Thu, 16 Oct 2025 09:00:00 -0500

Exclusive commercial rights secured for the nanobody-based CD22 binder for next-generation CAR applications like in vivo CAR-T and CAR-M
CD22 nanobody binder offers potential advantages compared to traditional antibody formats for treating relapsed/refractory B-cell cancers

VANCOUVER, British Columbia--(BUSINESS WIRE)-- ME Therapeutics Holdings Inc. (“ME Therapeutics” or the “Company”) (CSE: METX) (FSE: Q9T), a publicly listed biotechnology company working on novel cancer-fighting drugs in the field of immuno-oncology, today announced its subsidiary, ME Therapeutics Inc., has entered into a technology license agreement dated October 15, 2025 (the “License Agreement”) with the National Research Council of Canada (NRC)

ME Therapeutics Granted Licence for CD22 Nanobody Asset to Expand Next-Gen In Vivo CAR Cell Therapy Program

Thu, 16 Oct 2025 09:00:00 -0500

Exclusive commercial rights secured for the nanobody-based CD22 binder for next-generation CAR applications like in vivo CAR-T and CAR-M
CD22 nanobody binder offers potential advantages compared to traditional antibody formats for treating relapsed/refractory B-cell cancers

VANCOUVER, British Columbia--(BUSINESS WIRE)-- ME Therapeutics Holdings Inc. (“ME Therapeutics” or the “Company”) (CSE: METX) (FSE: Q9T), a publicly listed biotechnology company working on novel cancer-fighting drugs in the field of immuno-oncology, today announced its subsidiary, ME Therapeutics Inc., has entered into a technology license agreement dated October 15, 2025 (the “License Agreement”) with the National Research Council of Canada (NRC)

ME Therapeutics Granted Licence for CD22 Nanobody Asset to Expand Next-Gen In Vivo CAR Cell Therapy Program

Thu, 16 Oct 2025 09:00:00 -0500

Exclusive commercial rights secured for the nanobody-based CD22 binder for next-generation CAR applications like in vivo CAR-T and CAR-M
CD22 nanobody binder offers potential advantages compared to traditional antibody formats for treating relapsed/refractory B-cell cancers

VANCOUVER, British Columbia--(BUSINESS WIRE)-- ME Therapeutics Holdings Inc. (“ME Therapeutics” or the “Company”) (CSE: METX) (FSE: Q9T), a publicly listed biotechnology company working on novel cancer-fighting drugs in the field of immuno-oncology, today announced its subsidiary, ME Therapeutics Inc., has entered into a technology license agreement dated October 15, 2025 (the “License Agreement”) with the National Research Council of Canada (NRC)

ME Therapeutics Granted Licence for CD22 Nanobody Asset to Expand Next-Gen In Vivo CAR Cell Therapy Program

Thu, 16 Oct 2025 09:00:00 -0500

Exclusive commercial rights secured for the nanobody-based CD22 binder for next-generation CAR applications like in vivo CAR-T and CAR-M
CD22 nanobody binder offers potential advantages compared to traditional antibody formats for treating relapsed/refractory B-cell cancers

VANCOUVER, British Columbia--(BUSINESS WIRE)-- ME Therapeutics Holdings Inc. (“ME Therapeutics” or the “Company”) (CSE: METX) (FSE: Q9T), a publicly listed biotechnology company working on novel cancer-fighting drugs in the field of immuno-oncology, today announced its subsidiary, ME Therapeutics Inc., has entered into a technology license agreement dated October 15, 2025 (the “License Agreement”) with the National Research Council of Canada (NRC)

ME Therapeutics Granted Licence for CD22 Nanobody Asset to Expand Next-Gen In Vivo CAR Cell Therapy Program

Thu, 16 Oct 2025 09:00:00 -0500

Exclusive commercial rights secured for the nanobody-based CD22 binder for next-generation CAR applications like in vivo CAR-T and CAR-M
CD22 nanobody binder offers potential advantages compared to traditional antibody formats for treating relapsed/refractory B-cell cancers

VANCOUVER, British Columbia--(BUSINESS WIRE)-- ME Therapeutics Holdings Inc. (“ME Therapeutics” or the “Company”) (CSE: METX) (FSE: Q9T), a publicly listed biotechnology company working on novel cancer-fighting drugs in the field of immuno-oncology, today announced its subsidiary, ME Therapeutics Inc., has entered into a technology license agreement dated October 15, 2025 (the “License Agreement”) with the National Research Council of Canada (NRC)

ME Therapeutics Granted Licence for CD22 Nanobody Asset to Expand Next-Gen In Vivo CAR Cell Therapy Program

Thu, 16 Oct 2025 09:00:00 -0500

Exclusive commercial rights secured for the nanobody-based CD22 binder for next-generation CAR applications like in vivo CAR-T and CAR-M
CD22 nanobody binder offers potential advantages compared to traditional antibody formats for treating relapsed/refractory B-cell cancers

VANCOUVER, British Columbia--(BUSINESS WIRE)-- ME Therapeutics Holdings Inc. (“ME Therapeutics” or the “Company”) (CSE: METX) (FSE: Q9T), a publicly listed biotechnology company working on novel cancer-fighting drugs in the field of immuno-oncology, today announced its subsidiary, ME Therapeutics Inc., has entered into a technology license agreement dated October 15, 2025 (the “License Agreement”) with the National Research Council of Canada (NRC)

ME Therapeutics Granted Licence for CD22 Nanobody Asset to Expand Next-Gen In Vivo CAR Cell Therapy Program

Thu, 16 Oct 2025 09:00:00 -0500

Exclusive commercial rights secured for the nanobody-based CD22 binder for next-generation CAR applications like in vivo CAR-T and CAR-M
CD22 nanobody binder offers potential advantages compared to traditional antibody formats for treating relapsed/refractory B-cell cancers

VANCOUVER, British Columbia--(BUSINESS WIRE)-- ME Therapeutics Holdings Inc. (“ME Therapeutics” or the “Company”) (CSE: METX) (FSE: Q9T), a publicly listed biotechnology company working on novel cancer-fighting drugs in the field of immuno-oncology, today announced its subsidiary, ME Therapeutics Inc., has entered into a technology license agreement dated October 15, 2025 (the “License Agreement”) with the National Research Council of Canada (NRC)

ME Therapeutics Granted Licence for CD22 Nanobody Asset to Expand Next-Gen In Vivo CAR Cell Therapy Program

Thu, 16 Oct 2025 09:00:00 -0500

Exclusive commercial rights secured for the nanobody-based CD22 binder for next-generation CAR applications like in vivo CAR-T and CAR-M
CD22 nanobody binder offers potential advantages compared to traditional antibody formats for treating relapsed/refractory B-cell cancers

VANCOUVER, British Columbia--(BUSINESS WIRE)-- ME Therapeutics Holdings Inc. (“ME Therapeutics” or the “Company”) (CSE: METX) (FSE: Q9T), a publicly listed biotechnology company working on novel cancer-fighting drugs in the field of immuno-oncology, today announced its subsidiary, ME Therapeutics Inc., has entered into a technology license agreement dated October 15, 2025 (the “License Agreement”) with the National Research Council of Canada (NRC)

ME Therapeutics Added to CSE25 Index

Fri, 10 Oct 2025 09:00:00 -0500

VANCOUVER, British Columbia--(BUSINESS WIRE)-- ME Therapeutics Holdings Inc. (“ME Therapeutics” or the “Company”) (CSE: METX) (FSE: Q9T), a publicly listed biotechnology company discovering and developing novel cancer fighting drugs in the field of immuno-oncology, announced today it has been added to the CSE25 Index, a signature benchmark of the Canadian Securities Exchange.

The CSE25 Index is composed of the twenty-five largest companies by market capitalization listed on the CSE. This sub-index holds over 75% of the total market capitalization of the Composite Index, which is a gauge of the overall performance of companies listed on the CSE.

“We are